Recruiting
Phase 1
2025-524100-29-00
An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants with Active Sjogren’s Disease or Idiopathic Inflammatory Myopathy
Phase 1 – testing safety in a small group of people
Conditions:
Seropositive autoimmune disease: Sjogren’s disease or idiopathic inflammatory myopathy
Sponsor: Ouro Medicines Limited
trial.available_in:
БГ